跳至主要内容
临床试验/CTRI/2020/10/028322
CTRI/2020/10/028322已完成未知

Evaluating the benefits of Beta Glucan & Nano ECF (Entro-Coccus Faecalis) in children with ASD (Autism spectrum disorders) by analysis of gut microbiotaand related parameters

Medi Nippon Health Care Private Limited MD0 个研究点目标入组 17 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subjects aged less than 18 years
  • 2. Both male and female
  • 3. ASD criteria as per CARS (Childhood Autism Rating Scale) score
  • 4. Parents willing to consent for their children for actively participating in the study

排除标准

  • 1. Subjects aged more than 18 years old
  • 2. Any child with acute general illness or is on any antibiotic, anti-inflammatory, or antioxidant treatment for the last two weeks
  • 3. Hyperallergic to any of the investigational products
  • 4. Subjects with long standing infections

研究者

发起方
Medi Nippon Health Care Private Limited MD

相似试验